Fate Therapeutics, Inc. - FATE STOCK NEWS

Fate Therapeutics (NASDAQ: FATE) expands its collaboration with ONO Pharmaceutical to develop CAR NK and CAR T-cell candidates targeting solid tumors. This enhanced partnership includes ONO contributing novel binding domains for a second solid tumor antigen. Fate will lead preclinical development, with ONO having an option for global commercialization. The deal ensures ongoing research funding for Fate and potential milestone payments, including tiered royalties on net sales. Fate's innovative iPSC product platform supports mass production of engineered cell products for cancer treatments.

Fate Therapeutics (NASDAQ: FATE) will present at the 2022 Jefferies Global Healthcare Conference on June 10, 2022, at 9:00 AM ET in New York. The company focuses on developing programmed cellular immunotherapies for cancer patients, leveraging its proprietary induced pluripotent stem cell (iPSC) platform. A live webcast of the presentation will be available in the Investors section of the company's website, with an archived version accessible shortly after the event.

Fate Therapeutics, a clinical-stage biopharmaceutical company focused on cellular immunotherapies, announced its participation in two upcoming investor conferences. The BofA Securities 2022 Healthcare Conference will be held on May 12, 2022, at 12:20 PM ET in Las Vegas, Nevada. Additionally, the H.C. Wainwright Annual Global Life Sciences Conference will be available on demand starting May 24, 2022, at 7:00 AM ET. Interested investors can access live webcasts of the presentations on the company’s website. Fate Therapeutics aims to develop innovative cell therapies for cancer treatment.

Fate Therapeutics (NASDAQ: FATE) reported significant advancements in Q1 2022, with ongoing patient enrollment in multiple trials for its CAR T-cell therapies aimed at treating relapsed/refractory B-cell lymphoma and acute myeloid leukemia. Notably, FT596's clinical protocol combining it with R-CHOP will be submitted to the FDA in 2Q22. The company holds $641.7 million in cash and investments and recorded $18.4 million in revenue, largely from collaborations. However, R&D expenses totaled $72.1 million, highlighting an ongoing financial commitment to innovation.

Fate Therapeutics, a clinical-stage biopharmaceutical company, will host a conference call on May 4, 2022, at 5:00 PM ET to discuss its first quarter 2022 financial results and provide a corporate update. Participants can join via phone or listen to the live audio webcast available on the company’s website. Fate Therapeutics is focused on developing first-in-class programmed cellular immunotherapies targeting cancer patients, utilizing its proprietary iPSC product platform for creating off-the-shelf NK and T-cell therapies.

Onxeo S.A. has appointed Dr. Shefali Agarwal as the new President and CEO, succeeding Julien Miara. Dr. Agarwal, previously Chief Medical and Development Officer at Epizyme, has extensive experience in oncology and drug development. The company plans to prepare for a U.S. Pre-IND meeting for its DDR inhibitor, AsiDNA®, and aims to build infrastructure in the U.S. A recent private financing will extend Onxeo's runway into Q2 2023.

Fate Therapeutics (NASDAQ: FATE), a biopharmaceutical firm focused on cellular immunotherapies for cancer, announced its participation in three upcoming investor conferences. These include the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 11:10 AM ET, the Barclays Global Healthcare Conference on March 16, 2022, at 11:45 AM ET, and the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 8:00 AM ET. Each presentation will be available on-demand, with recordings accessible via the Company's website shortly after the events.

Fate Therapeutics reported encouraging clinical progress in its therapies for B-cell malignancies during its Q4 2021 earnings release. The company highlighted a 69% objective response rate (ORR) and 56% complete response (CR) in its FT596+R study. The FDA granted RMAT designation to FT516 for r/r DLBCL, expediting its development. Financially, Fate holds $716.6 million in cash, with Q4 revenue at $17.1 million. However, a projected GAAP loss from operations for 2022 is estimated between $335 million to $365 million, with cash use expected at $290 million to $315 million.

Fate Therapeutics announced plans for a conference call on February 28, 2022, at 5:00 PM ET to discuss its fourth quarter and full year 2021 financial results and provide a corporate update. Interested parties can join via phone or through a live audio webcast accessible on the company's website. Fate Therapeutics specializes in programmed cellular immunotherapies for cancer, leveraging its proprietary induced pluripotent stem cell product platform to develop innovative NK and T-cell therapies.